Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase

Kunihiro Hosono, Hiroki Endo, Hirokazu Takahashi, Michiko Sugiyama, Takashi Uchiyama, Kaori Suzuki, Yuichi Nozaki, Kyoko Yoneda, Koji Fujita, Masato Yoneda, Masahiko Inamori, Akiko Tomatsu, Takeshi Chihara, Kan Shimpo, Hitoshi Nakagama, Atsushi Nakajima

研究成果: Article査読

147 被引用数 (Scopus)


Metformin is widely used for the treatment of diabetes mellitus. Adenosine monophosphate-activated protein kinase (AMPK) is known to be activated by metformin and to inhibit the mammalian target of rapamycin (mTOR) pathway. The mTOR pathway plays an important role in the protein translational machinery and cell proliferation. We examined the effect of metformin on the suppression of colorectal carcinogenesis in chemical carcinogen-induced models. Seven-wk-old BALB/c mice were intraperitoneally (i.p.) injected with azoxymethane (AOM, 10mg/kg) and then treated with or without metformin (250mg/kg/d) for 6 wk (for the investigation of aberrant crypt foci [ACF] formation) or 32 wk (for polyp formation). We next investigated colonic epithelial proliferation using bromodeoxyuridine (BrdU) and the proliferating cell nuclear antigen (PCNA) labeling indices. Furthermore, to examine the indirect effect of metformin, the insulin resistance status and the serum lipid levels were assessed. Treatment with metformin significantly reduced ACF formation. The effect of metformin on colon polyp inhibition was relatively modest. No significant difference in body weight or glucose concentration was observed. The BrdU and PCNA indices decreased in mice treated with metformin. A Western blot analysis revealed that the phosphorylated mTOR, S6 kinase, and S6 protein levels in the colonic mucosa decreased significantly in mice treated with metformin. In conclusion, metformin suppresses colonic epithelial proliferation via the inhibition of the mTOR pathway through the activation of AMPK. As metformin is already used daily as an antidiabetic drug, it might be a safe and promising candidate for the chemoprevention of colorectal cancer.

ジャーナルMolecular Carcinogenesis
出版ステータスPublished - 01-07-2010

All Science Journal Classification (ASJC) codes

  • 分子生物学
  • 癌研究


「Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。